Market Research Logo

Global Opthalmic Therapeutic Market 2015-2019

Global Opthalmic Therapeutic Market 2015-2019

About Ophthalmic Diseases

Ophthalmology is the science of eyes. It is the branch of medicine concerned with the treatment of eye-related diseases and eye defects. Some of the common eye disorders are glaucoma, retinal diseases, conjunctivitis, refractive errors, color blindness, and retinitis. Many of the eye diseases do not show symptoms at early stages. They will be painless with no defect in vision until the disease progresses to an advanced stage. Regular eye checkups must be done to detect the development of any disorder. Proper care and hygiene must be ensured to protect the eyes.

Technavio's analysts forecast the global ophthalmic therapeutic market to grow at a CAGR of 6.53% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global ophthalmic therapeutic market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies, OTC drugs, and generics along with the drugs used as off-label for the treatment of ophthalmic disorders such as:

  • Glaucoma
  • Dry eye syndrome
  • Retinal disorders such as diabetic retinopathy, macular edema, RVO, and AMD
Technavio's report, Global Ophthalmic Therapeutic Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of global ophthalmic therapeutic market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.Key Regions
  • Americas
  • APAC
  • EMEA
Key Vendors
  • Actavis
  • Bayer
  • F. Hoffmann-La Roche
  • Merck
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
Other Prominent Vendors
  • Acadia Pharmaceuticals
  • AC Immune
  • Acorn Biomedical
  • Acucela
  • Advanced Cell Technology
  • Aerie Pharmaceuticals
  • Alcon
  • Alexion Pharmaceuticals
  • Alimera Sciences
  • Allergan
  • Ampio Pharmaceuticals
  • Antisense Therapeutics
  • Avalanche Biotechnologies
  • BCN Peptides
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Carl Zeiss Meditec
  • Eleven Biotherapeutics
  • Falcon Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline
  • Glycadia
  • Icon Bioscience
  • iCo Therapeutics
  • Inotek Pharmaceuticals
  • Intellect Neurosciences
  • Isis Pharmaceuticals
  • Kowa Group
  • Laboratorios Sophia
  • Lexicon Pharmaceuticals
  • Lpath
  • Neurotech Pharma
  • NicOx
  • Numoda Capital
  • OPKO Health
  • Ophthotech Corporation
  • Ohr Pharmaceutical
  • Otsuka Pharmaceutical
  • PanOptica
  • Parexel International
  • Promedior
  • pSivida
  • Quark Pharmaceuticals
  • R-Tech Ueno
  • Santen Pharmaceutical
  • Seikagaku
  • Senju Pharmaceutical
  • Shire
  • SIFI
  • Sirnaomics
  • StemCells
  • ThromboGenics
  • Valeant Pharmaceuticals
Market Driver
  • Increase in Prevalence of Eye Diseases
  • For a full, detailed list, view our report
Market Challenge
  • Lack of Awareness
  • For a full, detailed list, view our report
Market Trend
  • Strategic Alliances
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Opthalmic Therapeutic Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Opthalmic Therapeutic Market: Actavis, Bayer, F. Hoffmann-La Roche, Merck, Novartis, Pfizer and Regeneron Pharmaceuticals

Other Prominent Vendors in the market are: Acadia Pharmaceuticals, AC Immune, Acorn Biomedical, Acucela, Advanced Cell Technology, Aerie Pharmaceuticals, Alcon, Alexion Pharmaceuticals, Alimera Sciences, Allergan, Ampio Pharmaceuticals, Antisense Therapeutics, Avalanche Biotechnologies, BCN Peptides, Boehringer Ingelheim, Bristol-Myers Squibb, Carl Zeiss Meditec, Eleven Biotherapeutics, Falcon Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Glycadia, Icon Bioscience, iCo Therapeutics, Inotek Pharmaceuticals, Intellect Neurosciences, Isis Pharmaceuticals, Kowa Group, Laboratorios Sophia, Lexicon Pharmaceuticals, Lpath, Neurotech Pharma, NicOx, Numoda Capital, OPKO Health, Ophthotech Corporation, Ohr Pharmaceutical, Otsuka Pharmaceutical, PanOptica, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Santen Pharmaceutical, Seikagaku, Senju Pharmaceutical, Shire, SIFI, Sirnaomics, StemCells, ThromboGenics and Valeant Pharmaceuticals

Commenting on the report, an analyst from Technavio’s team said: “The market presents huge growth opportunities for vendors. Companies are increasingly forming strategic alliances and engaging in M&A to increase their market share. As the development cost of ophthalmic drugs is high, small biotechnology firms are forming alliances with big pharmaceutical companies for product development. For instance, F. Hoffman-La Roche collaborated with Novartis for the development of Lucentis. According to the terms of the partnership, F. Hoffman-La Roche markets the drug in the US, while Novartis markets it outside the US.Similar strategic partnerships among vendors can propel the market growth.”

According to the report, the incidence of eye diseases is increasing worldwide, particularly in industrialized and middle-income countries. Changing dietary habits, unhealthy lifestyles, and increased use of electronic equipment such as computers, TVs, and videogames affect normal eyesight. Smoking increases an individual’s chances of developing AMD by 2-3 times. Similarly, individuals with diets high in fat, cholesterol, and sugar and low in antioxidants are more likely to be affected by AMD. People with diabetes have a higher risk of being affected by diabetic retinopathy and macular edema. The population of people with diabetes is likely to increase from 382 million in 2013 to 592 million by 2035, leading to a rise in individuals with DME. The total number of cases of diabetic retinopathy is expected to increase from 4.89 million in 2012 to 7.17 million by 2022. The WHO classifies glaucoma as the second leading cause of visual impairment in the world, affecting about 285 million people worldwide.

Further, the report states that the limited public awareness of eye diseases restricts the market growth.

Companies Mentioned

Actavis, Bayer, F. Hoffmann-La Roche, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Acadia Pharmaceuticals, AC Immune, Acorn Biomedical, Acucela, Advanced Cell Technology, Aerie Pharmaceuticals, Alcon, Alexion Pharmaceuticals, Alimera Sciences, Allergan, Ampio Pharmaceuticals, Antisense Therapeutics, Avalanche Biotechnologies, BCN Peptides, Boehringer Ingelheim, Bristol-Myers Squibb, Carl Zeiss Meditec, Eleven Biotherapeutics, Falcon Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Glycadia, Icon Bioscience, iCo Therapeutics, Inotek Pharmaceuticals, Intellect Neurosciences, Isis Pharmaceuticals, Kowa Group, Laboratorios Sophia, Lexicon Pharmaceuticals, Lpath, Neurotech Pharma, NicOx, Numoda Capital, OPKO Health, Ophthotech Corporation, Ohr Pharmaceutical, Otsuka Pharmaceutical, PanOptica, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Santen Pharmaceutical, Seikagaku, Senju Pharmaceutical, Shire, SIFI, Sirnaomics, StemCells, ThromboGenics, Valeant Pharmaceuticals

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
    • Table Major Ophthalmic Conditions
  • Disease Overview
    • Glaucoma
      • Understanding the Disease
      • Types of Glaucoma
        • Table Types of Glaucoma
      • Etiology
      • Signs and Symptoms
      • Diagnosis
      • Management
      • Epidemiology
    • Dry Eye Syndrome
      • Understanding the Disease
      • Types of Dry Eye Syndrome
      • Causes of Dry Eye Syndrome
      • Risk Factors of Dry Eye Syndrome
      • Signs and Symptoms
      • Diagnosis
      • Management
    • Diabetic Retinopathy
      • Understanding the Disease
      • Etiology
        • Table Development of Diabetic Retinopathy
      • Diagnosis
      • Classification
        • Table Classification of Diabetic Retinopathy
      • Epidemiology
      • Management
    • RVO
      • Understanding the Disease
      • Types of RVO
        • Table Types of RVO
      • Etiology
      • Diagnosis
      • Management
    • AMD
      • Understanding the Disease
      • Stages of AMD
      • Types of AMD
        • Table Types of AMD
      • Etiology
      • Signs and Symptoms
      • Diagnosis
      • Management
    • Macular Edema
      • Understanding the Disease
      • Etiology
      • Diagnosis
      • Management
    • Economic Burden of Ophthalmic Diseases
  • Pipeline Analysis
    • Pipeline Portfolio: Glaucoma
      • Rhopressa
      • Roclatan
      • Trabodenoson
      • Lomerizine HCl
      • Y-39983
    • Pipeline Portfolio: Dry Eye Syndrome
      • Lifitegrast
      • OPC-12759E
      • EBI-005
    • Pipeline Portfolio: Diabetic Retinopathy
      • Squalamine
      • K-115-R/Ripasudil Hydrochloride Hydrate
    • Pipeline Portfolio: AMD
      • Anecortave Acetate (Suspension)
      • E10030
      • Abicipar
    • Pipeline Portfolio: RVO
      • TLC399
      • AGN208397
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Ophthalmic Therapeutics Market 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Disease Type
    • Global Ophthalmic Therapeutics Market by Disease Type
      • Table Global Ophthalmic Therapeutics Market by Disease Type
    • Glaucoma
    • Dry Eye Syndrome
    • Retinal Disorders
      • Diabetic Retinopathy
      • Macular Edema
      • AMD
      • RVO
        • Table Global Ophthalmic Therapeutics Market by Disease Type 2014
    • Global Glaucoma Therapeutics Market
      • Market Size and Forecast
        • Table Global Glaucoma Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global Glaucoma Therapeutics Market
    • Global AMD Therapeutics Market
      • Market Size and Forecast
        • Table Global AMD Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global AMD Therapeutics Market
    • Global Macular Edema Therapeutics Market
      • Market Size and Forecast
        • Table Global Macular Edema Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global Macular Edema Therapeutics Market
    • Global Dry Eye Syndrome Therapeutics Market
      • Market Size and Forecast
        • Table Global Dry Eye Syndrome Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global Dry Eye Syndrome Therapeutics Market
    • Global Diabetic Retinopathy Therapeutics Market
      • Market Size and Forecast
        • Table Global Diabetic Retinopathy Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global Diabetic Retinopathy Therapeutics Market
    • Global RVO Therapeutics Market
      • Market Size and Forecast
        • Table Global RVO Therapeutics Market 2014-2019 ($ millions)
        • Table Key Takeaways: Global RVO Therapeutics Market
        • Table Global Ophthalmic Therapeutics Market: YoY Growth Rate and Revenue by Disease Type 2014-2019
  • Market Segmentation by Route of Administration
    • Table Global Ophthalmic Therapeutics Market by Route of Administration
    • Topical
    • Systemic
      • IV
      • Oral
    • Intravitreal
  • Market Segmentation by Molecule Type
    • Table Global Ophthalmic Therapeutics Market by Molecule Type
    • Biologics
    • Small Molecules
  • Market Segmentation by Dosage Form
    • Table Global Ophthalmic Therapeutics Market by Dosage Form
    • Solutions
    • Implants
    • Pills
  • Geographical Segmentation
    • Global Ophthalmic Therapeutics Market by Geography 2014-2019
      • Table Global Ophthalmic Therapeutics Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
    • Table Major Drivers of Global Ophthalmic Therapeutics Market
  • Drivers and Their Impact
  • Market Challenges
    • Table Major Challenges in Global Ophthalmic Therapeutics Market
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Major Trends in Global Ophthalmic Therapeutics Market
  • Trends and Their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Vendor Ranking 2014
      • Novartis
        • Table Novartis: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
      • Actavis
        • Table Actavis: YoY Revenue of Restasis 2012-2014 ($ millions)
        • Table Actavis: YoY Revenue of Lumigan 2012-2014 ($ millions)
        • Table Actavis: YoY Revenue of Alphagan, Alphagan P, and Combigan 2012-2014 ($ millions)
      • F. Hoffmann-La Roche
        • Table F. Hoffmann-La Roche: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
      • Regeneron Pharmaceuticals
        • Table Regeneron Pharmaceuticals: YoY Revenue and Growth Rate of Eylea 2011-2014 ($ millions)
      • Bayer
        • Table Bayer: YoY Revenue and Growth Rate of Eylea 2012-2014 ($ millions)
      • Pfizer
        • Table Pfizer: YoY Revenue and Growth Rate of Xalatan/Xalacom 2012-2014 ($ millions)
      • Merck
    • Other and Future Prominent Vendors
  • Key Vendor Analysis
    • Actavis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Actavis: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Actavis: Business Segmentation by Revenue 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Actavis: Sales by Geography ($ millions)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Bayer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table Bayer: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
      • Geographical Segmentation by Revenue 2014
        • Table Bayer: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Merck
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Merck: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
      • Sales by Geography
        • Table Merck: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Novartis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Novartis: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Pfizer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table Pfizer: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
      • Geographical Segmentation by Revenue 2014
        • Table Pfizer: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Key developments
      • SWOT Analysis
    • Regeneron Pharmaceuticals
      • Key Facts
      • Business Overview
      • Product Segmentation
        • Table Regeneron Pharmaceuticals: Product Segmentation
      • Revenue Product Segmentation
        • Table Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
  • Other Reports in This Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report